Alzai Health Corp. · TSXV:ALZI
Alzai Health — Investor Presentation (October 2026)
19 slides from Alzai Health's investor presentation, October 2026
Slide 1: Practical AI Platform for Disease Risk Stratification
Investor Deck Practical AI Platform for Disease Risk Stratification *Predict. Prevent. Transform ALZAI Health Corp. | TSXV: ALZI | FRA: H2F | October 2026 *Alzai's platform is a risk-screening and clinical decision-support tool. It is not a diagnostic test and does not itself prevent or treat diseas
Slide 2: Legal Disclaimer
Legal Disclaimer THIS MANAGEMENT PRESENTATION (the "presentation") was prepared as a summary overview and economic benefits of the Company’s technologies. Forward-looking information is only of the current aDairs of ALZAI Health Corp. (“ALZAI Health" or the “Company"). generally identifiable by words
Slide 3: Identifying Underdiagnosed Disease Earlier - at Scale
OUR MISSION Identifying Underdiagnosed Disease Earlier - at Scale Our mission is to empower healthcare systems, pharmaceutical companies, payers and digital health platforms with the predictive intelligence needed to identify high-risk populations before disease progression creates avoidable clinica
Slide 4: Investment Highlights
INVESTMENT CASE Investment Highlights AI-powered risk screening platform for underdiagnosed chronic diseases, using routine clinical data to identify hidden individuals at risk - built on a validated Alzheimer’s foundation and scalable across diseases and markets. ALZAI Health Corp. | TSXV: ALZI | F
Slide 5: Healthcare is Still Reactive
THE MACRO PROBLEM Healthcare is Still Reactive Many Chronic diseases often progress silently for years, while patients are typically identified only after symptoms or clinical deterioration.¹ This creates a structural gap across healthcare: • Disease begins before symptoms • Healthcare data exists,
Slide 6: A Scalable Risk-Screening Architecture
PLATFORM ARCHITECTURE A Scalable Risk-Screening Architecture ALZAI’s platform is designed to analyze routine healthcare data to generate disease-specific risk insights. The platform can ingest and analyze existing clinical data, apply proprietary AI models, stratify risk across patient populations a
Slide 7: Alzheimer's Disease: A Massive Clinical and Economic Burden
ALZHEIMER’S MARKET OPPORTUNITY Alzheimer’s Disease: A Massive Clinical and Economic Burden Alzheimer’s Disease remains one of the largest and most costly healthcare challenges globally. The burden is growing rapidly as populations age, while diagnosis continues to occur too late for many patients. 3
Slide 8: Patient Identification: A Massive Unmet Need in Alzheimer's Disease
ALZHEIMER’S IDENTIFICATION GAP Patient Identification: A Massive Unmet Need in Alzheimer’s Disease Patients are typically identified only after cognitive decline becomes visible and the diagnostic pathway begins. This creates a major gap: • Early disease is often clinically silent • Screening relies
Slide 9: Alzheimer's Risk Stratification
ALZAI SOLUTION Alzheimer’s Risk Stratification ALZAI uses routine, pre-existing patient data to flag individuals at risk of being diagnosed positive for Alzheimer’s and stratify them by timeframe. Core Capabilities: • Uses routine, pre-existing demographics, standard blood panels and chronic disease
Slide 10: Large-Scale Clinical Validation
ALZAI VALIDATION Large-Scale Clinical Validation Validated on 1.6M+ patient records across U.S. and Israeli populations, demonstrating consistent performance across large-scale real-world datasets. ✓ Validation across U.S. and Israeli populations ✓ Prediction horizon up to 10 years ALZAI Health Corp
Slide 11: Multiple Markets for One Platform
ALZAI PRODUCT ECOSYSTEM Multiple Markets for One Platform ALZAI’s Alzheimer’s risk stratification platform can be deployed across multiple healthcare sectors, each with a distinct customer need and commercial use case. ALZAI Health Corp. | TSXV: ALZI | FRA: H2F | Slide 11
Slide 12: A Silent Epidemic with Major Market Potential
LIVER DISEASE MARKET OPPORTUNITY A Silent Epidemic with Major Market Potential Liver disease remains widely underdiagnosed, with fibrosis often progressing silently until advanced stages. Rising metabolic disease is increasing the need for earlier risk identification. 1 3 2 4 1. Comparing similariti
Slide 13: Predictive Liver Disease Risk Stratification
LIVAI SOLUTION Predictive Liver Disease Risk Stratification LivAI is designed to integrate into healthcare workflows and use routine clinical data to calculate liver fibrosis risk, flag high-risk individuals and prioritize diagnostic referral. Core Capabilities: • Calculates fibrosis risk using exis
Slide 14: LivAI Clinical Validation
LIVAI VALIDATION LivAI Clinical Validation LivAI has been evaluated using large-scale real-world healthcare data and, in a prospective clinical evaluation, identified approximately 3 times as many patients with positive FibroScan results (>8 kPa) compared with traditional FIB-4 screening. * These re
Slide 15: Competitive Advantages
COMPETITIVE ADVANTAGES Competitive Advantages ALZAI’s platform is differentiated by its combination of real-world validation, proprietary AI, workflow integration and disease expansion potential. ALZAI Health Corp. | TSXV: ALZI | FRA: H2F | Slide 15
Slide 16: Scalable Commercial Model Across Multiple Healthcare Channels
BUSINESS MODEL Scalable Commercial Model Across Multiple Healthcare Channels ALZAI's platform can be monetized across multiple enterprise and healthcare channels, depending on customer type, workflow and deployment model. ALZAI Health Corp. | TSXV: ALZI | FRA: H2F | Slide 16
Slide 17: Designated to Support Upstream Risk Identification Across Healthcare Pathways
STRATEGIC POSITIONING Designated to Support Upstream Risk Identification Across Healthcare Pathways ALZAI's platform is designed to analyze existing healthcare data before downstream clinical decisions are made. ALZAI Health ALZAICorp. Health | TSXV: Corp. ALZI | TSXV: | FRA:ALZI H2F|| Slide 16 17
Slide 18: Meet the Team Behind ALZAI
OUR TEAM Meet the Team Behind ALZAI A multidisciplinary team combining expertise in healthcare, AI, data science, clinical research and commercialization. ALZAI Health Corp. | TSXV: ALZI | FRA: H2F | Slide 18
Slide 19: Thank You
Thank You ALZAI Health Corp. 22 Adelaide St W #3400, Toronto, ON M5H 4E3, Canada Phone: +1 (416) 862 4351 Email: [email protected] Website: www.alzaihealth.com ALZAI Health Corp. | TSXV: ALZI | FRA: H2F | October 2026